论文部分内容阅读
Clinically, myocardial ischemia-reperfusion injury usually occur in patients undergoing percutaneous coronary intervention (PCI) surgery.Epoxyeicosatrienoic acid (EET), a well-known CYP pathway metabolite of arachidonic acid, can reduce reperfusion injury by dilating coronary artery and its anti-inflammatory effects.In vivo, EETs are often metabolized into DHET by soluble epoxide hydrolase (sEH), while their cardiovascular protective effects are significantly weakened.